N
Nemysis
We are focussed on nutritional and pharmaceutical solutions to cope with Iron Deficiency/Anemia and Gluten Intolerance
About Nemysis
Developer of bio-photonics and artificial intelligence technology designed to stratify patients for clinical trials. The company's technology uses a non-invasive, portable, inexpensive system to screen for Alzheimer's and other neurodegenerative diseases, enabling healthcare companies to make clinical trials less expensive, more convenient, and patient-centric.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Dublin, Ireland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
European Innovation Council
Horizon Europe
European Union
Series A1 investor entered at this stage
Kolinpharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nemysis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nemysis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.